Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XORTX Therapeutics Inc ( (TSE:XRTX) ) has provided an announcement.
On April 1, 2026, XORTX Therapeutics Inc. reported that it has secured all necessary approvals from the TSX Venture Exchange and Nasdaq Stock Exchange to proceed with a share consolidation at a ratio of one new common share for every five old common shares. The consolidation, scheduled to take effect on April 6, 2026, is a capital-structure move that could support continued listing compliance and potentially improve trading dynamics as the company advances its late-stage kidney and gout drug programs.
The announcement underscores XORTX’s effort to align its share structure with the expectations of major exchanges while it pushes forward several near-clinical and clinical assets in kidney and metabolic disease. For investors and other stakeholders, the consolidation marks a notable adjustment in the company’s equity base that may influence share price optics and liquidity, without altering the underlying fundamentals of its drug development pipeline.
The most recent analyst rating on (TSE:XRTX) stock is a Sell with a C$0.48 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on XRTX Stock
According to Spark, TipRanks’ AI Analyst, XRTX is a Neutral.
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn despite some improvement) and bearish technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. Its pipeline includes three clinically advanced candidates—XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and other organ injury linked to respiratory virus infections—alongside a preclinical program, XRx-225, targeting Type 2 diabetic nephropathy and uric-acid–related pathways.
Average Trading Volume: 4,210
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$3.55M
See more data about XRTX stock on TipRanks’ Stock Analysis page.